Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies

Table 4 Comparison of the primary outcomes between the first- and second-line treatments in the included studies

	ORR		DCR		PFS-16w			OS-12 m	OS-6 m
	n	95% CI	n	95% C	n	95% C	n	95% C	n	95% C
Overall	342	0.126 (0.063,0.190)	221	0.603 (0.473,0.733)	221	0.502 (0.382,0.622)	298	0.437 (0.329,0.546)	298	0.739 (0.664,0.813)
First line	162	0.103 (0.015,0.191)	51	0.530 (0.393,0.667)	51	0.353 (0.222,0.484)	162	0.408 (0.332,0.483)	162	0.703 (0.633,0.773)
Second line	180	0.145 (0.044,0.247)	170	0.620 (0.465,0.775)	170	0.545 (0.433,0.656)	136	0.443 (0.243,0.644)	136	0.757 (0.632,0.882)
P values	0.089		0.174		0.012		0.048		0.050

Note: Grade 3–4 AEs was obtained by adding all the adverse events in grade 3–4 together. ORR objective response rate, DCR disease control rate, PFS-16w progression-free survival rate at 16 weeks, OS-12 m overall survival rate at 12 months; OS-6 m overall survival rate at 6 months

ISSN: 1471-2407